Guerbet SA

Guerbet's capital structure is characterized by a lack of dilution risk, as the number of basic and diluted shares outstanding is identical at 12.6 million shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. This lack of liquidity data limits the ability to evaluate the company's short-term financial flexibility.

Profitability and return metrics are not available in the current valuation snapshot, which prevents a direct comparison with industry_config preferred metrics or cohort medians. Without access to key profitability indicators such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess Guerbet's performance relative to its peers in the Advanced Medical Equipment & Technology industry.

Segment and geographic exposure data are not disclosed in the available financial snapshot, making it difficult to evaluate revenue concentration or geographic diversification. This lack of transparency limits the ability to assess potential risks from over-reliance on specific product lines or regions.

Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or revenue history. Analysts have issued a mean price target of 11.60 EUR and a median of 12.00 EUR, with no strong buy or buy recommendations, and two hold ratings. This suggests a cautious outlook from the investment community.

Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The absence of balance-sheet data and going-concern language in source documents raises concerns about financial transparency. Dilution risk is currently low, but the lack of detailed capital structure data limits the ability to evaluate future dilution potential.

Recent events and filings do not appear to be disclosed in the available data, which limits the ability to assess any material developments that may impact the company's operations or financial position. The absence of transcripts or recent filings suggests a lack of public disclosure activity.

Revenue €198.7M, −1,3% YoY.

• ▍Revenue €198.7M, −1,3% YoY

Revenue €178.2M.

• ▍Revenue €178.2M

Revenue €786.4M, −6,5% YoY; Operating income −277,9% YoY.

• ▍Revenue €786.4M, −6,5% YoY
• ▍Operating income −277,9% YoY
• ▍Net income −773,6% YoY
• ▍Free cash flow −586,3% YoY
• ▍Net margin -13.8%

Revenue €841.1M, +7,0% YoY; Operating income +28,2% YoY.

• ▍Revenue €841.1M, +7,0% YoY
• ▍Operating income +28,2% YoY
• ▍Net income −32,6% YoY
• ▍Free cash flow −38,6% YoY
• ▍Net margin 1.9%

Revenue €785.7M, +4,3% YoY; Operating income +312,9% YoY.

• ▍Revenue €785.7M, +4,3% YoY
• ▍Operating income +312,9% YoY
• ▍Net income +158,1% YoY
• ▍Free cash flow +311,6% YoY
• ▍Net margin 3.0%

Revenue €753.3M, +2,9% YoY; Operating income −146,9% YoY.

• ▍Revenue €753.3M, +2,9% YoY
• ▍Operating income −146,9% YoY
• ▍Net income −226,0% YoY
• ▍Free cash flow −84,0% YoY
• ▍Net margin -5.5%

Revenue €732.1M; Operating income €38.7M.

• ▍Revenue €732.1M
• ▍Operating income €38.7M
• ▍Net margin 4.5%